Table 1. Characteristic of the included studies.
| Trial | Year | Patients enrolled | Treatment arms (N) | Median age, years (range) | Median PFS (mos) | Median OS (mos) | Median follow-up (mos) | Jadad Score |
|---|---|---|---|---|---|---|---|---|
| COU-AA-301 (phase III) |
2011 | 1185 | Abiraterone + Prednisone (791) | 69 (42-95) | 5.6 | 14.8 | 12.8 | 5 |
| Prednisone (394) | 69 (39-90) | 3.6 | 10.9 | |||||
| COU-AA-302 (phase III) |
2013 | 1082 | Abiraterone + Prednisone (542) | 71 (44-95) | 16.5 | nr | 22.2 | 5 |
| Prednisone (540) | 70 (44-90) | 8.3 | 27.2 | |||||
| AFFIRM (phase III) |
2012 | 1199 | Enzalutamide (800) | 69 (41-92) | 8.3 | 18.4 | 14.4 | 5 |
| Placebo (399) | 69 (49-89) | 3.0 | 13.6 | |||||
| PREVAIL (phase III) |
2014 | 1717 | Enzalutamide (872) | 72 (43-93) | 11.2 | 32.4 | 22.0 | 5 |
| Placebo (845) | 71 (42-93) | 2.8 | 30.2 |